| Title |
Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN)
|
|---|---|
| Published in |
Journal of Neuroimmune Pharmacology, April 2013
|
| DOI | 10.1007/s11481-013-9451-y |
| Pubmed ID | |
| Authors |
Pradeep Chopra, Mark S. Cooper |
| Abstract |
Complex Regional Pain Syndrome (CRPS) is a neuropathic pain syndrome, which involves glial activation and central sensitization in the central nervous system. Here, we describe positive outcomes of two CRPS patients, after they were treated with low-dose naltrexone (a glial attenuator), in combination with other CRPS therapies. Prominent CRPS symptoms remitted in these two patients, including dystonic spasms and fixed dystonia (respectively), following treatment with low-dose naltrexone (LDN). LDN, which is known to antagonize the Toll-like Receptor 4 pathway and attenuate activated microglia, was utilized in these patients after conventional CRPS pharmacotherapy failed to suppress their recalcitrant CRPS symptoms. |
X Demographics
The data shown below were collected from the profiles of 51 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 20 | 39% |
| United Kingdom | 3 | 6% |
| Canada | 2 | 4% |
| Ireland | 2 | 4% |
| Spain | 1 | 2% |
| Austria | 1 | 2% |
| Denmark | 1 | 2% |
| Unknown | 21 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 41 | 80% |
| Practitioners (doctors, other healthcare professionals) | 6 | 12% |
| Scientists | 2 | 4% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
| Unknown | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 161 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| Portugal | 1 | <1% |
| Unknown | 158 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 23 | 14% |
| Researcher | 21 | 13% |
| Student > Bachelor | 18 | 11% |
| Student > Master | 15 | 9% |
| Student > Doctoral Student | 15 | 9% |
| Other | 41 | 25% |
| Unknown | 28 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 82 | 51% |
| Agricultural and Biological Sciences | 11 | 7% |
| Nursing and Health Professions | 10 | 6% |
| Neuroscience | 6 | 4% |
| Psychology | 5 | 3% |
| Other | 15 | 9% |
| Unknown | 32 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2023.
All research outputs
#770,213
of 25,654,806 outputs
Outputs from Journal of Neuroimmune Pharmacology
#23
of 602 outputs
Outputs of similar age
#5,304
of 213,438 outputs
Outputs of similar age from Journal of Neuroimmune Pharmacology
#2
of 16 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 602 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,438 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.